Nevakar Injectables Portfolio

About Nevakar

Nevakar is a private, clinical-stage biotech company repositioning established drugs for improved outcomes in ophthalmology through novel formulations and delivery systems. Its strategy leverages known active ingredients to potentially accelerate development and reduce risk. The company's most advanced program, NVK002 for pediatric myopia progression, is under regulatory review in China and has completed Phase 3 trials in the US, positioning it as a near-term catalyst. Nevakar's business model spans both therapeutics and a proprietary drug delivery platform.

Therapeutic Areas

Other Ophthalmic diseases (unspecified) Drugs